UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference

Core Insights - UroGen Pharma Ltd. will present at the Guggenheim Securities Healthcare Innovation Conference from November 10-12, 2025 [1] - The presentation is scheduled for November 11, 2025, at 10:30 AM ET, and will include 1x1 investor meetings [2] Company Overview - UroGen Pharma is focused on developing and commercializing innovative solutions for urothelial and specialty cancers, emphasizing the need for better treatment options [3] - The company has developed RTGel, a proprietary sustained-release hydrogel technology aimed at improving the therapeutic profiles of existing drugs [3] - UroGen's first product is approved for treating low-grade upper tract urothelial cancer, while its second product is the first FDA-approved medication for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer [3] - Both products are designed to ablate tumors through non-surgical means [3]